AFT Pharmaceuticals - Near-term goals in sight with FY23 momentum
AFT Pharmaceuticals reported another strong fiscal year, capping off three consecutive years of double-digit top-line growth. FY23 revenues of...
214 Views
AFT Pharmaceuticals: FY23 Preview — Story Remains Intact
We expect AFT Pharmaceuticals' (AFT) underlying FY23 result to show strong growth, led by its Australia and New Zealand segments, when it reports...
205 Views
AFT Pharmaceuticals - Maxigesic IV closer to FDA approval
AFT Pharmaceuticals has announced that the US FDA has allocated a Prescription Drug User Fee Act (PDUFA) date for Maxigesic IV, an intravenous form...
149 Views
AFT Pharmaceuticals - Maxigesic international momentum continues
AFT Pharmaceuticals (AFT) has announced that it has signed three additional licensing agreements for Maxigesic IV – with Labatec in Switzerland and...
207 Views
AFT Pharmaceuticals: Breaking the Pain Barrier
AFT Pharmaceuticals' (AFT) notification of US FDA approval for its rapid release tablet form of Maxigesic provides a material long-term opportunity.
275 Views